Aspira Women's Health Inc. — fact timeline

John (Jack) Fraser was appointed as Interim Chief Executive Officer at Aspira Women's Health Inc..

“appointed John (Jack) Fraser as Interim Chief Executive Officer”

Michael Buhle departed as Chief Executive Officer at Aspira Women's Health Inc..

“Michael Buhle ceased serving as the Company’s Chief Executive Officer effective June 17, 2026”

John Fraser was appointed as Interim Chief Executive Officer at Aspira Women's Health Inc..

“Effective June 17, 2026, the board of directors (the “Board”) of the Company appointed John Fraser, the Company’s current Chairman of the Board, to serve as its Interim Chief Executive Officer while a search of internal and external candidates is conducted.”

Michael Buhle departed as Chief Executive Officer at Aspira Women's Health Inc..

“On June 17, 2026, Michael Buhle ceased serving as Chief Executive Officer of Aspira Women's Health Inc. (the "Company").”

Aspira Women's Health Inc. shareholders approved Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm at the 2026-06-17 meeting.

“Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 22,810,174 15,244 95,198 0”

Aspira Women's Health Inc. shareholders approved Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan at the 2026-06-17 meeting.

“Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan The Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 5,000,000 shares so that a total of 9,532,818 shares of common stock are authorized to be granted under the 2019 Plan, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 5,654,497 624,233 72,187 16,569,699”

Aspira Women's Health Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-17 meeting.

“Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2026, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 5,568,783 505,829 276,305 16,569,699”

Aspira Women's Health Inc. issued up to 4,455,000 shares of common stock of warrant to accredited and institutional investors.

“warrants (the “Common Warrants”) to purchase up to 4,455,000 shares of the Company’s Common Stock, at a purchase price of $0.45 per share of Common Stock and accompanying warrants.”

Aspira Women's Health Inc. issued 3,300,000 shares of common stock to accredited and institutional investors for $0.45 per share.

“for the issuance and sale in a private placement (the “Private Placement”) of (i) 3,300,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”) and (ii) warrants (the “Common Warrants”) to purchase up to 4,455,000 shares of the Company’s Common Stock, at a purchase price of $0.45 per share of Common Stock and accompanying warrants.”

Aspira Women's Health Inc. entered into Purchase Agreement with accredited and institutional investors valued at approximately $1.485 million (effective 2026-06-05).

“On June 5, 2026, Aspira Women’s Healthcare Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreement”) with accredited and institutional investors (“the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 3,300,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”) and (ii) warrants (the “Common Warrants”) to purchase up to 4,455,000 shares of the Company’s Common Stock, at a purchase price of $0.45 per share of Common Stock and accompanying warrants.”

Aspira Women's Health Inc. entered into Master Collaboration and License Agreement with Cleveland Clinic Foundation valued at Partnering fee of $125,000 total, payable $50,000 within 30 days, then $25,000 on first, second, and (effective 2026-05-20).

“On May 20, 2026, Aspira Women’s Health Inc. (“Aspira”) announced that it had entered into a Master Collaboration and License Agreement (the “Agreement”) with Cleveland Clinic Foundation (“CCF”), a non-profit educational, research and health care institution.”

Brian Hungerford departed as Chief Financial Officer at Aspira Women's Health Inc..

“On April 26, 2026, the consulting agreement between the Company and Hungerford Consulting LLC, under which Brian Hungerford had served as Chief Financial Officer, terminated at the request of Hungerford Consulting LLC.”

John Strahley was appointed as Chief Financial Officer and Chief Accounting Officer at Aspira Women's Health Inc..

“On April 26, 2026, Aspira Women's Health, Inc. (the "Company") appointed John Strahley as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026.”

Aspira Women's Health Inc. entered into Laboratory Services Agreement with Mayo Collaborative Services, Inc. d/b/a Mayo Clinic Laboratories valued at Not disclosed (effective 2025-12-16).

“On December 23, 2025, Aspira Women’s Health Inc. (“Aspira”) disclosed that we had entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”), effective as of December 16, 2025.”

Aspira Women's Health Inc. incurred term loan of $1,050,000 with Agile Lending, LLC at interest charges of $441,000 (assuming all payments are made on time) maturing August 26, 2026.

“On January 30, 2026, Aspira Women’s Health Inc. (the “ Company ”) entered into a Subordinated Business Loan and Security Agreement (the “ Subordinated Loan Agreement ”) with Agile Lending, LLC, as lead lender, and Agile Capital Funding, LLC, as collateral agent, pursuant to which the Lenders (as such term is defined in the Subordinary Loan Agreement) agreed to make a secured term loan to the Company and certain subsidiary co-borrowers. The Subordinated Loan Agreement is dated as of January 30, 2026. ​ The term loan is evidenced by a Subordinated Secured Promissory Note (the “ Note ”) in the form attached to the Subordinated Loan Agreement. The Note was issued in the principal amount of $1,050,000, will include interest charges of $441,000 (assuming all payments are made on time), and is scheduled to mature on August 26, 2026.”

Aspira Women's Health Inc. entered into Subordinated Loan Agreement with Agile Lending, LLC, as lead lender, and Agile Capital Funding, LLC, as collateral agent valued at $1,050,000 (effective 2026-01-30).

“On January 30, 2026, Aspira Women’s Health Inc. (the “ Company ”) entered into a Subordinated Business Loan and Security Agreement (the “ Subordinated Loan Agreement ”) with Agile Lending, LLC, as lead lender, and Agile Capital Funding, LLC, as collateral agent”

Aspira Women's Health Inc. issued common stock to Lincoln Park Capital Fund, LLC for up to an aggregate of $10.0 million.

“On December 23, 2025, Aspira Women’s Health Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase, at the Company’s direction from time to time, up to an aggregate of $10.0 million of the Company’s common stock”

Aspira Women's Health Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at $10.0 million (effective 2025-12-23).

“On December 23, 2025, Aspira Women’s Health Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase, at the Company’s direction from time to time, up to an aggregate of $10.0 million of the Company’s common stock”

Aspira Women's Health Inc. entered into Laboratory Services Agreement with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (effective 2025-12-16).

“On December 16, 2025, Aspira Women’s Health Inc. (“Aspira”) entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”).”

Aspira Women's Health Inc. issued up to 4,912,500 shares of warrant to accredited and institutional investors for $0.45 per share of Common Stock and accompanying warrants.

“stock, par value $0.001 (the “Common Stock”) and (ii) warrants (the “Common Warrants”) to purchase up to 4,912,500 shares of the Company’s Common Stock, at a purchase price of $0.45 per share of Common Stock and accompanying warrants. The Common Warrants are exercisable immediately upon issuance at an exercise price of $0.75 per share and have a term of”

Aspira Women's Health Inc. issued 6,550,000 shares of common stock to accredited and institutional investors for $0.45 per share.

“stock, par value $0.001 (the “Common Stock”) and (ii) warrants (the “Common Warrants”) to purchase up to 4,912,500 shares of the Company’s Common Stock, at a purchase price of $0.45 per share of Common Stock and accompanying warrants. The Common Warrants are exercisable immediately upon issuance at an exercise price of $0.75 per share and have a term of”

Aspira Women's Health Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 15, 2025, Aspira Women’s Health Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice indicated t”

Cynthia Hundorfean was appointed as director at Aspira Women's Health Inc..

“On April 6, 2025, the Board appointed John Fraser and Cynthia Hundorfean as directors of the Company.”

John Fraser was appointed as director at Aspira Women's Health Inc..

“On April 6, 2025, the Board appointed John Fraser and Cynthia Hundorfean as directors of the Company.”

Julie Carrillo was appointed as Principal Accounting Officer at Aspira Women's Health Inc..

“On April 4, 2025, the Board appointed Julie Carrillo, the Company’s Corporate Controller, to act as the Principal Accounting Officer of the Company on an interim basis.”

Jeffrey Cohen was appointed as director at Aspira Women's Health Inc..

“On April 2, 2025, the Board (the “Board”) of Directors of the Company appointed Jeffrey Cohen, M.D. as a director of the Company.”

Aspira Women's Health Inc.: Changed the quorum for stockholder meetings to one-third of shares issued and outstanding entitled to vote (effective 2025-03-28).

“On March 28, 2025, the Board of Directors of Aspira Women’s Health Inc. (the “Company”) approved an amendment of the Company’s Amended and Restated Bylaws (the “Bylaws”) to change the quorum for stockholder meetings to equal one-third (33.33%) of the shares issued and outstanding and entitled to vote on the matters at the meeting.”

James Crawford resigned as VP of Finance at Aspira Women's Health Inc..

“On March 21, 2025, James Crawford informed Mike Buhle, the Chief Executive Officer of Aspira Women’s Health Inc. (the “Company”) that he was resigning as VP of Finance of the Company, for personal reasons, effective April 4, 2025.”

Celeste Fralick resigned as director at Aspira Women's Health Inc..

“On March 15, 2025, Celeste Fralick informed the Board of Directors of Aspira Women’s Health Inc. (the “Company”) that she was resigning as a director of the Company, for personal reasons, effective March 31, 2025.”

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(c)).

“February 11, 2025, the Company received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) that based on the closing bid price per share immediately preceding entering into a binding agreement to issue the securities for the Private Placement of $1.47 per share plus $0.125 attributable to the value of the warrants, the market value of the transaction for purposes of Listing Rule 5625(c) was $1.595. Since the shares and warrants sold in the private placement were issued below the market value, and the Company failed to obtain shareholder approval, the Company violated Li”

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5635(c)).

“February 11, 2025, the Company received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) that based on the closing bid price per share immediately preceding entering into a binding agreement to”

Ellen Beausang was appointed as Director at Aspira Women's Health Inc..

“the Board of Directors of the Company appointed Ellen Beausang as a director of the Company.”

Sandra Milligan resigned as President at Aspira Women's Health Inc..

“Dr. Sandra Milligan, the President of Aspira Women’s Health Inc. (the “Company”) informed the Board of Directors of the Company that she was resigning as President of the Company for personal reasons, effective February 21, 2025.”

James Crawford was appointed as Vice President of Finance at Aspira Women's Health Inc..

“In addition, on January 28, 2025, the Board of Directors of Aspira Women’s Health Inc. (the “Company”) appointed James Crawford as the Company’s Vice President of Finance.”

Michael Buhle was appointed as Chief Executive Officer at Aspira Women's Health Inc..

“On January 28, 2025, the Board of Directors of Aspira Women’s Health Inc. (the “Company”) appointed Michael Buhle as the Company’s Chief Executive Officer in addition to his current duties as Chief Commercial Officer.”

Sandra Milligan was appointed as principal accounting officer at Aspira Women's Health Inc..

“The Company’s Chief Executive Officer, Dr. Sandra Milligan, will be the Company’s principal accounting officer for the present time.”

John Kallassy resigned as Interim Chief Financial Officer at Aspira Women's Health Inc..

“accepted the resignation for personal reasons of John Kallassy, the Company’s Interim Chief Financial Officer, effective on January 10, 2025.”

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“December 31, 2024, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Nasdaq Capital Market by January 7, 2025 and pays Nasdaq a hearing fee of $20,000, the Company’s common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 10, 2025. While the Company intends to appeal Nasdaq’s decision, no guarantee can be provided tha”

John Ragard was appointed as director at Aspira Women's Health Inc..

“On July 29, 2024, Aspira Women’s Health Inc. (the “Company”) issued a press release announcing the appointment of John Ragard as a director, effective July 25, 2024.”

Nicole Sandford was appointed as Chief Financial Officer (interim) at Aspira Women's Health Inc..

“As of June 27, 2024, Nicole Sandford, the Company’s Chief Executive Officer, has taken over Dr. Hombeck’ s duties on an interim basis until a search for his replacement is completed.”

Torsten Hombeck departed as Chief Financial Officer at Aspira Women's Health Inc..

“On June 27, 2024, the Compensation Committee (the “Committee”) of Aspira Women’s Health Inc. (the “Company”) determined that a personal civil matter interfered with Dr. Torsten Hombeck’ s ability to continue to serve as the Company’s Chief Financial Officer.”

Torsten Hombeck was appointed as Corporate Secretary at Aspira Women's Health Inc..

“Dr. Hombeck was appointed as the Company's Corporate Secretary and his annual base salary was increased to $375,000 from $325,000 as of June 1, 2024.”

Aspira Women's Health Inc. reported first quarter ended March 31, 2024 results: revenue $2.2 million. Guidance reaffirmed.

“by reference language in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Aspira Women’s Health Reports First Quarter 2024 Financial Results Q1 2024 OvaSuite SM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN,”

Aspira Women's Health Inc. shareholders approved Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm at the 2024-05-13 meeting.

“000 shares and increase the maximum number of awards that may be granted as incentive stock options under the 2019 Plan to a total of 3,000,000 shares, as set forth below:  FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,187,597 98,942 2,440 3,804,357 Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of BDO USA, LLP (n/k/a BDO P.C.) as the Company’s independent registered public accounting firm for the year ending December 31, 2024, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 7,992,912 88,066 12,358”

Aspira Women's Health Inc. shareholders approved Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan at the 2024-05-13 meeting.

“y’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2024, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,189,574 97,653 1,752 3,804,357 Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan The Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 1,000,000 shares and increase the maximum number of awards that may be granted as incentive stock options under the 2019 Plan to a total of 3,000,000 shares, as set forth below:  FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,187,597 98,942 2,440 3,804,357 Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accou”

Aspira Women's Health Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2024-05-13 meeting.

“4,214,222 73,859 898 3,804,357 Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2024, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 4,189,574 97,653 1,752 3,804,357 Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc.”

Aspira Women's Health Inc. shareholders approved Election of Directors at the 2024-05-13 meeting.

“NOMINEE FOR AGAINST ABSTENTIONS BROKER NON-VOTES Stefanie Cavanaugh 4,213,732 69,683 5,564 3,804,357”

Minh Merchant resigned as General Counsel at Aspira Women's Health Inc..

“Minh Merchant, the General Counsel, Chief Compliance Officer, and Corporate Secretary of Aspira Women’s Health Inc. (the “Company”) notified the Company that she will resign from these roles with the Company effective May 6, 2024.”

Aspira Women's Health Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue Product revenue was $2.1 million for the three months ended December 31, 2023.

“Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and twelve months ended December 31, 2023.”

Sandra Milligan was appointed as President at Aspira Women's Health Inc..

“On March 16, 2024, Aspira Women’s Health Inc. (the “Company”) expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President, effective as of April 1, 2024”